Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
dc.contributor.author | Piñana, J.L. | |
dc.contributor.author | Xhaard, A. | |
dc.contributor.author | Tridello, G. | |
dc.contributor.author | Passweg, J. | |
dc.contributor.author | Kozijn, A. | |
dc.contributor.author | Polverelli, N. | |
dc.contributor.author | Heras, I. | |
dc.date.accessioned | 2021-06-10T19:38:18Z | |
dc.date.available | 2021-06-10T19:38:18Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1537-6613 | |
dc.identifier.uri | https://doi.org/10.1093/infdis/jiaa553 | |
dc.identifier.uri | http://hdl.handle.net/11446/4284 | |
dc.description | PubMed: 32860509 | en_US |
dc.description | 2-s2.0-85107087117 | en_US |
dc.description.abstract | BACKGROUND: Little is known about characteristics of seasonal human coronaviruses (HCoVs) (NL63, 229E, OC43, and HKU1) after allogeneic stem cell transplantation (allo-HSCT). METHODS: This was a collaborative Spanish and European bone marrow transplantation retrospective multicenter study, which included allo-HSCT recipients (adults and children) with upper respiratory tract disease (URTD) and/or lower respiratory tract disease (LRTD) caused by seasonal HCoV diagnosed through multiplex polymerase chain reaction assays from January 2012 to January 2019. RESULTS: We included 402 allo-HSCT recipients who developed 449 HCoV URTD/LRTD episodes. Median age of recipients was 46 years (range, 0.3-73.8 years). HCoV episodes were diagnosed at a median of 222 days after transplantation. The most common HCoV subtype was OC43 (n?=?170 [38%]). LRTD involvement occurred in 121 episodes (27%). HCoV infection frequently required hospitalization (18%), oxygen administration (13%), and intensive care unit (ICU) admission (3%). Three-month overall mortality after HCoV detection was 7% in the whole cohort and 16% in those with LRTD. We identified 3 conditions associated with higher mortality in recipients with LRTD: absolute lymphocyte count <0.1 × 109/mL, corticosteroid use, and ICU admission (hazard ratios: 10.8, 4.68, and 8.22, respectively; P?<?.01). CONCLUSIONS: Seasonal HCoV after allo-HSCT may involve LRTD in many instances, leading to a significant morbidity. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | NLM (Medline) | en_US |
dc.identifier.doi | 10.1093/infdis/jiaa553 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | seasonal human coronavirus | en_US |
dc.subject | allogeneic hematopoietic stem cell transplantation | en_US |
dc.subject | community-acquired respiratory virus | en_US |
dc.subject | HCoV-229E | en_US |
dc.subject | HCoV-HKU1 | en_US |
dc.subject | HCoV-NL63 | en_US |
dc.subject | HCoV-OC43 | en_US |
dc.subject | immunocompromised | en_US |
dc.subject | immunodeficiency score index | en_US |
dc.subject | multiplex PCR assay | en_US |
dc.subject | upper and lower respiratory tract disease | en_US |
dc.title | Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation | en_US |
dc.type | article | en_US |
dc.relation.journal | The Journal of infectious diseases | en_US |
dc.department | [0-Belirlenecek] | en_US |
dc.identifier.issue | 9 | en_US |
dc.identifier.volume | 223 | en_US |
dc.identifier.startpage | 1564 | en_US |
dc.identifier.endpage | 1575 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.institutionauthor | [0-Belirlenecek] | |
dc.department-temp | Piñana, J.L., Hematology Division, Hospital Universitario y Politécnico La FeValencia, Spain, Instituto Carlos IIIMadrid, Spain; Xhaard, A., Service d'Hématologie-Greffe, Hôpital Saint-Louis, Université Paris-Diderot, Paris, France; Tridello, G., Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy; Passweg, J., University Hospital Basel, Basel, Switzerland; Kozijn, A., European Society for Blood and Marrow Transplantation Data Office Leiden, Leiden, Netherlands; Polverelli, N., Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy; Heras, I., Hematology Division, Hospital Morales MeseguerMurcia, Spain; Perez, A., Hematology Division, Hospital Clínico de ValenciaValencia, Spain; Sanz, J., Hematology Division, Hospital Universitario y Politécnico La FeValencia, Spain, Instituto Carlos IIIMadrid, Spain; Berghuis, D., Willem Alexander Children's Hospital/Leiden University Medical Center, Leiden, Netherlands; Vázquez, L., Hematology Division, Hospital Universitario de Salamanca, Salamanca, Spain; Suárez-Lledó, M., Hematology Division, Hospital Clínic, Barcelona, Spain; Itäla-Remes, M., Turku University Hospital, Turku, Finland; Ozcelik, T., Demiroglu Bilim UniversityIstanbul, Turkey; Iturrate Basarán, I., Hematology Division, Hospital de la PrincesaMadrid, Spain; Karakukcu, M., Erciyes University, Faculty of Medicine, Erciyes Pediatric Bone Marrow Transplant CenterKayseri, Turkey; Al Zahrani, M., King Abdulaziz Medical City, Riyadh, Saudi Arabia; Choi, G., University Medical Center Groningen, University of GroningenGroningen, Netherlands; Cuesta Casas, M.A., Hematology Division, Hospital Regional de Málaga, Malaga, Spain; Batlle Massana, M., Hematology Division, Instituto Catalan de Oncologia-Hospital Germans Trias i Pujol, Barcelona, Spain; Viviana, A., Universita Cattolica S. Cuore, Rome, Italy; Blijlevens, N., Radboud University Medical Center, Nijmegen, Netherlands; Ganser, A., Department of Hematology, Hemostasis, Oncology, Stem Cell Transplantation. Hannover Medical School, Hannover, Germany; Kuskonmaz, B., Hacettepe University Children's HospitalAnkara, Turkey; Labussière-Wallet, H., Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France; Shaw, P.J., Children's Hospital at Westmead, Sydney, Australia; Arzu Yegin, Z., Gazi University Faculty of MedicineAnkara, Turkey; González-Vicent, M., Pediatric Division, Niño Jesus Children's HospitalMadrid, Spain; Rocha, V., Hospital Sirio-Libanes, São Paulo, Brazil; Ferster, A., Children's University Hospital Queen Fabiola, Université Libre de Bruxelles, Brussels, Belgium; Knelange, N., Service d'Hématologie-Greffe, Hôpital Saint-Louis, Université Paris-Diderot, Paris, France; Navarro, D., Hematology Division, Hospital Morales MeseguerMurcia, Spain; Mikulska, M., University of Genoa (Dipartimento di Scienze della Salute) and Istituto Nazionale per la Ricerca sul Cancro Ospedale Policlinico San Martino, Genova, Italy; de la Camara, R., Hematology Division, Hospital de la PrincesaMadrid, Spain; Styczynski, J., Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun Uniwersytet Miko?aja Kopernika, University Hospital, Bydgoszcz, Poland | en_US |
Bu öğenin dosyaları:
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
PubMed İndeksli Yayınlar Koleksiyonu [1488]
PubMed Indexed Publications Collection -
Scopus İndeksli Yayınlar Koleksiyonu [1747]
Scopus Indexed Publications Collection